The Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are clonal disorders characterized by common mutations, but with distinct clinical features, treatment considerations, and prognostic outlooks.
Gabriela S. Hobbs, MD, Raajit K. Rampal, MD, PhD
Advertisement
Articles by Gabriela S. Hobbs, MD, Raajit K. Rampal, MD, PhD
Advertisement
Latest Updated Articles
JAK2 Mutations and JAK Inhibitors in the Management of Myeloproliferative NeoplasmsPublished: January 31st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5